Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
In Africa and Asia where the occurrence of mycotoxins is common and a high percentage of the population is infected with hepatitis B or C mycotoxin reduction is obligatory [8]
We, for one, are skeptical that providers' investments in AI are truly prompting payers to expand their own AI strategyproviders have very clearly lagged payers when it comes to AI investment and revenue cycle sophistication
During the 6-month follow-up period, 69.6% ( n = 10,430) of patients had 1 dose escalation and the mean (SD) time to first dose escalation was 59.1 (40.9) days
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
November 2025 Third-party Refinancing Process Beginning November 3, 2025, Lazard engaged over 15 prospective third-party capital providers to evaluate a potential refinancing of certain funded debt facilities
US$ 22.42
US$ 26.19
US$ 26.89
US$ 27.27
US$ 26.14
US$ 21.87
US$ 20.27
.png&w=828&q=100)
US$ 27.06
US$ 24.55
US$ 24.44
US$ 21.22
US$ 28.81
